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Nivolumab is anovel therapeutic option inNSCLC, associatedwith a significant survival
gain compared with Docetaxel. However, predictive biomarkers are lacking. The
presence of systemic inflammation has been correlated with poor outcome in many
cancer types. We aimed to evaluate whether there is a correlation between some
indicators of inflammation and response to Nivolumab or Docetaxel in pre-treated
NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed.
Baseline neutrophilia and thrombocytosis were not associated with response. High
dNLRwas associatedwith no response toNivolumab, but notwithDocetaxel, whereas
high PLR correlated with low treatment response in both groups. Among refractory
patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR
levels were observed compared with the overall population. This is one of the first
reports in this field and suggests that indicators of inflammation might be included
together with other predictive biomarkers in the baseline evaluation of patients
candidate for immunotherapy.
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1 | INTRODUCTION
Nivolumab is a novel therapeutic option in 2nd line Non Small Cell Lung
Cancer (NSCLC)with both squamous andnon-squamoushistology (Paz-
Ares, Horn, Spigel, Steins, & Ready, 2015; Reckamp, Baas, Crinò,
Eberhardt, & Poddubskaya, 2015). However, predictive biomarkers are
lacking. PD-L1 IHCexpressionhasbeenextensively studied inNSCLCas
potential predictive biomarker of response to anti-PD1/PD-L1 agents
with contrasting results and is now adopted as selection criteria for
Pembrolizumab in both 1st and 2nd line therapy (Herbst et al., 2016;
Reck et al., 2016).
Tumor-promoting inflammation is an established hallmark of
cancer, as chronic inflammation is a consistent feature of tumor
microenvironment (Galdiero, Garlanda, Jaillon, Marone, & Mantovani,
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2013; Hanahan & Weinberg. 2011). In addition, the presence of
systemic inflammation correlates with poor outcome in many cancer
types, including NSCLC. The immune cell composition of NSCLC is
dominated by neutrophils (Kargl et al., 2017) and recently several
authors correlated the presence of high neutrophil-to-lymphocyte ratio
(NLR) and/or high absolute neutrophil count (ANC) with poor prognosis
and lower response to conventional treatments in NSCLC (Carus et al.,
2013; Derman et al., 2017; Kang et al., 2017; Scilla et al., 2017). Similar
findings were reported for high platelet-to-lymphocyte ratio (PLR)
(Gu et al., 2016; Sanchez-Salcedo et al., 2016).
We aimed to evaluate whether there is a correlation between
some indicators of inflammation status, including neutrophilia, high
NRL, and high PLR with response in pretreated NSCLC patients
receiving Nivolumab or Docetaxel.
2 | MATERIALS AND METHODS
In this retrospective monocentric study twenty-eight consecutive
patients with NSCLC receiving Nivolumab were included. Baseline
white cell count (WBC) and absolute neutrophil count (ANC) were
collected and correlated with tumor response. Thirty-four NSCLC
patients treated with Docetaxel were used as controls. An
ANC ≥7500 cell/μl was defined as neutrophilia. Derived
neutrophil-to-lymphocyte ratio (dNLR) was calculated as:
ANC/(WBC-ANC). Platelet-to-lymphocyte ratio (PLR) was defined
as platelet count (PLT)/lymphocyte count. dNLR ≥3 and PLR ≥160
were defined high. PLT ≥450 × 103/µl was defined as thrombocy-
tosis (Ferrucci et al., 2016; Kim et al., 2016). Categorical variables
were compared using chi-square or Fisher's exact test. Overall
survival (OS) was defined as time from Nivolumab or Docetaxel start
to death and Progression Free Survival (PFS) as time from treatment
start to Progression Disease (PD) or death for any cause. OS and PFS
survival were estimated using the Kaplan–Meier method. Survival
curves were compared using the log-rank test. To estimate the
hazard ratio (HR), Cox regression analysis was used. Statistical
analyses were performed with the R program version 3.3.2.
3 | RESULTS
Baseline characteristics of patients in our cohort are reassumed in
Table 1. In the study population, median age was 68 years (range
45–82), 77% were male (89.3% in the Nivolumab group vs. 67.7% in
the Docetaxel group, p = 0.0004) and the predominant histology was
adenocarcinoma (48%), followed by squamous (40%), andmixed/other
histotypes (12%). Most patients were current or former smokers (90%)
with an equal distribution between the subgroups (p = 0.3572). Among
non-squamous patients, 16.2% were EGFR mutated and 8.1% were
KRAS-mutated, with an equal distribution in both treatment groups
(p = 0.0649 for EGFR mutations and p = 0.9188 for KRAS mutations).
The majority of patients received Nivolumab or Docetaxel as second
line therapy (69.3%),with no statistical differences between subgroups
(p = 0.205).
The overall response rate (ORR) in the study population, according
to RECIST 1.1, was 12.5%with Nivolumab versus 9.0%with Docetaxel
(p = 0.568); moreover, 8.3% of patients treated with Nivolumab
experienced unconventional responses.
ORRs according to baseline inflammation markers are reassumed
in Table 2. Baseline neutrophilia was detected in 18% and 26% of
patients in the Nivolumab and Docetaxel subgroups, respectively, and
thrombocytosis was found in 3.5% and 3% of patients, respectively.
Baseline neutrophilia and thrombocytosis were associated with a
significant reduction in the probability of response both in the global
study population (p = 0.0003 and p = 0.0018, respectively) and in
Nivolumab (p = 0.0001 and p = 0.0004, respectively) and Docetaxel
(p = 0.0006 and p = 0.0042, respectively) subgroups. High dNLR was
associated with lower ORRs with Nivolumab (p = 0.0001), whereas no
statistically significant differences were observed in the total study
population (p = 0.0787) and in patients treated with Docetaxel
(p = 0.9319). Conversely, a high PLR predicted a poor response in
the overall study population (p = 0.0407) and in the two treatment
subgroups (p < 0.0004 and p = 0.0094 for Nivolumab and Docetaxel,
respectively).
Moreover, we analyzed the baseline characteristics of refractory
patients (i.e., progressive disease as best response) compared with the
global study population. We found a higher incidence of thrombocy-
tosis (7% and 5%, p = 0.765), neutrophilia (28.5% and 40%, p = 0.117),
high PLR (75% and 50%, p = 0.0004), and high dNLR levels (28.5% and
55%, p = 0.0002) in this poor prognosis subgroup compared with the
overall cohort of patients.
After a median follow-up of 17.0 months (range 3–58), median
PFS in the study population was 4.0 months with Nivolumab (CI
95%, 2.0-NA), corresponding to a 6-month PFS rate of 40% (CI 95%,
25–65), and 2.0 months with Docetaxel (CI 95%, 2.0–5.0),
corresponding to a 6-month PFS rate of 23.5% (CI 95%, 13–43).
This difference was not statistically significant (p = 0.0934; HR 0.64).
Patients with no baseline neutrophilia tended to have longer PFS
than those with neutrophilia in the whole study population (4.0 vs.
2.0 months; p = 0.223) (Figure 1a) and in both Nivolumab (6.0 vs. 1.0
months; p = 0.209) and Docetaxel (3.0 vs. 2.0 months; p = 0.003)
subgroups (Figures 1b and 1c).
Patients with high and low dNLR experienced similar PFS (2.5 vs.
3.0 months; p = 0.19) in the global study population (Figure 2a), as well
as in patients treated with Nivolumab (1.0 vs. 4.0 months; p = 0.924)
(Figure 2b), and Docetaxel (2.5 vs. 3.0 months; p = 0.204) (Figure 2c). A
high PLR (≥160) predicted a poor PFS (2.0 vs. 5.0 months) (Figure 3a),
albeit this difference was not statistically significant (p = 0.172). No
differences were reported when analyzing the two treatment
subgroups with Nivolumab (6.0 vs. 6.0 months, p = 0.437) and
Docetaxel (3.0 vs. 3.0, p = 0.961). Median OS in the study population
was 5.0 months (CI 95%, 3–12) with Docetaxel and 6.0 months with
Nivolumab (CI 95%, 3-NA), with no statistical significant differences
(p = 0.456; HR 0.81). High dNLR predicted a poor OS in both overall
population (3.5 vs. 9.0 months; p = 0.05) (Figure 2d) and with
Nivolumab (2.0 vs. 6.0 months, p = 0.789) (Figure 2e) and Docetaxel
(3.5 vs. 8.5 months, p = 0.071) (Figure 2f). Moreover, neutrophilia
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predicted a poorer OS in all patients (2.0 vs. 9.0 months, p = 0.005)
(Figure 1d) and also in the Nivolumab (2.0 vs. 9.0 months, p = 0.245)
(Figure 1e) and Docetaxel (2.0 vs. 8.0 months, p = 0.003) (Figure 1f)
subgroups.
Finally, patients with high PLR levels tended to have a shorter OS
in the overall population (4.0 vs. 12.0 months, p = 0.085) (Figure 3b)
and with both Nivolumab (6.0 vs. 10.0 months, p = 0.756) and
Docetaxel (4.0 vs. 8.5 months, p = 0.352) compared to those with
PLR levels <160, albeit these differences were not statistically
significant.
4 | DISCUSSION
Immune checkpoint inhibitors are rapidly re-shaping the therapeutic
landscape of NSCLC in both pre-treated and chemotherapy naïve
TABLE 2 Overall response rates (ORRs) according to baseline dNLR, PLR, neutrophilia, and thrombocytosis in the total study population and in
treatment subgroups
High dNLR (%) Low dNLR (%) p value
ORR in the total population 5.26 13.51 p = 0.0787
ORR in the Nivolumab subgroup 0 15.78 p = 0.0001
ORR in the Docetaxel subgroup 12.5 11.11 p = 0.9319
High PLR (%) Low PLR (%) p value
ORR in the total population 4.35 13.63 p = 0.0407
ORR in the Nivolumab subgroup 8.3 46.15 p < 0.0004
ORR in the Docetaxel subgroup 0 8.33 p = 0.0094
Neutrophilia (%) No neutrophilia (%) p value
ORR in the total population 0 14.28 p = 0.0003
ORR in the Nivolumab subgroup 0 15.78 p = 0.0001
ORR in the Docetaxel subgroup 0 13.04 p = 0.0006
Thrombocytosis (%) No thrombocytosis (%) p value
ORR in the total population 0 11.11 p = 0.0018
ORR in the Nivolumab subgroup 0 13.63 p = 0.0004
ORR in the Docetaxel subgroup 0 9.68 p = 0.0042
TABLE 1 Baseline characteristics of patients in our cohort
All (62 patients) Nivolumab (28 patients) Docetaxel (34 patients) p value
Median age 68 years (45-82) 69 years (47-78) 68 years (45-82) 0.9315
Sex 0.0004
Male 77% 89.3% 67.7%
Female 23% 10.7% 32.3%
Smoking status 0.3572
Former/current smokers 90% 93% 88.2%
Never smokers 10% 7% 11.8%
Histology
Squamous 40% 60.8% 23.5% <0.0002
Adenocarcinoma 48% 39.2% 55.9% 0.0262
Mixed histology/other 12% 0% 20.6% <0.0005
Biomolecular status (non-SqCC only)
EGFR-mutated 16.2% 9.1% 19.2% 0.0649
EGFR wild-type 83.8% 90.9% 80.8% 0.0649
KRAS mutated 8.1% 9.1% 7.7% 0.9188
Treatment lines 0.205
2nd line 69.3% 64.2% 73.5%
≥3 lines 30.7% 35.8% 26.5%
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patients (Borghaei et al., 2015; Brahmer et al., 2015; Herbst et al.,
2016; Reck et al., 2016; Rittmeyer et al., 2017) with unprecedented
results in terms of overall survival. However, the advent of this
innovative class of anticancer agents brings several novel challenges in
clinical practice, such as new response criteria (Seymour et al., 2017),
novel potential patterns of progression (Champiat et al., 2016),
undeniable high costs (Matter-Walstra et al., 2016), and most
importantly the need of predictive biomarkers for patients selection.
PD-L1 immunohistochemical expression is the best-studied predictive
biomarker to anti-PD1/PD-L1 agents. However, the use of this
biomarker for patient selection poses different biological and technical
issues (Kerr et al., 2015; Patel & Kurzrock, 2015) and has produced
contrasting results in clinical trials, with a significant proportion of
patients responding to these agents even in absence of PD-L1
expression (Borghaei et al., 2015; Brahmer et al., 2015; Rittmeyer et al.,
2017). Several different predictive biomarkers beyond PD-L1 IHC
expression have been studied (Chen et al., 2016;Daud et al., 2016; Prat
et al., 2017; Rizvi et al., 2015), but to date none has entered into clinics.
Moreover, in some instances the clinical implementation of these
methodologies is difficult due to high costs and high level of expertise
required.
Inflammatory reaction results in chronic illnesses, including
cancer (Rajendran et al., 2018). Inflammation is a hallmark of cancer
and is a known driver of cancer development and progression.
Different markers of inflammation have been investigated in NSCLC
and other solid tumors and correlated with poor outcome and low
therapeutic response. dNLR and PLR, in addition to neutrophilia and
thrombocytosis are the most well-studied markers of systemic
FIGURE 1 Kaplan–Meier curves for PFS and OS according to the absolute neutrophil count (ANC) levels. (a) PFS in the study population;
(b) PFS in the Nivolumab subgroup; (c) PFS in the Docetaxel subgroup; (d) OS in the study population; (e) OS in the Nivolumab subgroup; (f)
OS in the Docetaxel subgroup
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inflammation in cancer and can be easily performed in clinical
practice.
Tumor microenvironment and immune system play a central role
in response to immunomodulating agents (Nishino, Ramaiya, Hatabu, &
Hodi, 2017) and, recently, it has been reported that neutrophils
dominate the immune cell composition in NSCLC (Kargl et al., 2017).
Here, we demonstrated that the presence of some indicators of
systemic inflammation, such as baseline neutrophilia, thrombocytosis,
high dNLR, and high PLR are associated with poor outcome in pre-
treated NSCLC and with low response to both Nivolumab and
chemotherapy. These data confirm the poor prognostic role of these
indicators inNSCLC, as previously reported (AkinciOzyurek et al., 2017;
Gu et al., 2016; Kang et al., 2017; Scilla et al., 2017).Moreover, recently,
some authors have correlated high pre-treatment dNLR and/or PLR
levels with inferior outcomes in advanced NSCLC after treatment with
Nivolumab (Bagley et al., 2017; Diem et al., 2017). These data are in line
with our present analysis and suggest the utility of dNLR and PLR,
besides other predictive biomarkers, for selection of patients to
PD-1/PD-L1 axis inhibitors in NSCLC. In addition, we correlated the
presence of baseline neutrophilia with outcome, demonstrating a
negative predictive role in terms of PFS and OS in pre-treated
unselected NSCLCs with both chemotherapy and immunotherapy.
Our study presents some limitations. First, the retrospective
nature of this analysis that may have introduced potential bias and
confounding factors. However, in this monocentric study, were
included all consecutive NSCLC patients treated with Nivolumab or
FIGURE 2 Kaplan–Meier curves for PFS and OS according to the derived neutrophil-to-lymphocyte ratio (dNLR). (a) PFS in the study
population; (b) PFS in the Nivolumab subgroup; (c) PFS in the Docetaxel subgroup; (d) OS in the study population; (e) OS in the Nivolumab
subgroup; (f) OS in the Docetaxel subgroup
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Docetaxel, limiting the potential bias of selection inherited in this type
of analyses. Second, the IHC status of PD-L1 was available only in a
minor fraction of patients, since it was not performed as routine clinical
practice at the time of patients’ treatment, and was not included in the
present analysis.
Future prospective studies, evaluating the role of these markers
of systemic inflammation in addition to other predictive biomarkers
will add further evidence of their potential role in the clinical
decision making in NSCLC. The wider use of PD-L1 testing after the
approval of Pembrolizumab in PD-L1+ ≥50% patients as first line
treatment and in PD-L1+ ≥1% patients in subsequent lines of
therapy will facilitate the correlation of PD-L1 status and markers of
systemic inflammation with the outcome after anti-PD1/PD-L1
inhibitors.
5 | CONCLUSIONS AND FUTURE
PERSPECTIVES
The results of this study suggest that indicators of inflammation such
as baseline neutrophilia, thrombocytosis, and high dNLR are usually
associated with a dismal prognosis and low efficacy of both
chemotherapy and immunotherapy in NSCLC. Given their relative
easy estimation, baseline evaluation of these indicators may be
included together with other predictive biomarkers in the baseline
evaluation of patients candidate for immunotherapy.
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